Showing 1 - 10 of 15
Background Palbociclib and Ribociclib are cyclin-dependent kinase 4/6 oral molecular inhibitors that have the potential to improve overall survival (OS), progression-free survival (PFS), and quality of life in patients with metastatic breast cancer (MBC). The objective of this study was to...
Persistent link: https://www.econbiz.de/10014500641
Persistent link: https://www.econbiz.de/10003785779
Persistent link: https://www.econbiz.de/10003353856
Persistent link: https://www.econbiz.de/10001405864
Persistent link: https://www.econbiz.de/10008824875
Persistent link: https://www.econbiz.de/10003384488
Persistent link: https://www.econbiz.de/10011392476
Persistent link: https://www.econbiz.de/10011404627
Persistent link: https://www.econbiz.de/10000991177
Persistent link: https://www.econbiz.de/10012199098